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Background
The clinical and economic impact of severe drug hyper-
sensitivity is huge for both healthcare and pharmaceutical
industry; however, no method for predicting culprit candi-
date t drugs under clinical development exists currently.
As genetic variants in human-leukocyte antigens (HLA)
have been linked to inter-individual differences in the risk
of drug hypersensitivity, we ascertained whether HLA
library can serve as a drug screening tool for their poten-
tial to cause severe drug hypersensitivity.
Method
We cloned and generated stable cell lines expressing one
common HLA allele, and then purified each HLA protein
genetically linked to particular hypersensitivity, immobi-
lized on a protein chip and analyzed the interaction
between HLA and drugs by surface plasmon resonance
(SPR) analysis.
Results
With HLA library coating on the chip, the direct interac-
tion between specific HLA protein complexes and culprit
drugs were detected by SPR analysis. For example, HLA-
B*1502 protein interacted with aromatic anti-epileptic
drugs, such as carbamazepine (CBZ), CBZ analogs
(10,11-eposide CBZ, oxcarbazepine, licabazepine and esli-
carbazepine), phenytoin (PHT), and lamotrigine (LTG),
but not structure-unrelated compounds, such as gaba-
pentin (GBP), levetiracetam (LEV), and topiramate
(TPN); In addition to HLA-B*1502, other HLA-B75
members could also present CBZ, whereas HLA-B62 and
HLA-B72 members could not, consistent with pharmaco-
genetic data. Moreover, HLA-B*5801 binds to allopurinol
and oxypurinol, but not febuxostat. Similar, HLA-B*5701
could interact with the nucleoside reverse transcriptase
inhibitor, abacavir, but not the non-nucleoside reverse
transcriptase inhibitor, nevirapine.
Conclusion
These data suggested the possibility of using HLA
library which contains different HLA molecules for its
ability to bind drug as a screen tool to screen drugs for
their potential to cause severe drug hypersensitivity.
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